22 October 2021 | News
Designed to remove risk and improve time, cost and compliance
image credit- shutterstock
EY has announced the launch of EY Smart Reviewer, a new technology-driven solution for the life sciences industry. It leverages artificial intelligence (AI) and natural language processing to help accelerate and improve the process to review materials used to market pharmaceutical and medical device products.
The EY Smart Reviewer solution makes it possible for pharmaceutical and medical technology companies to automate the Medical, Legal, Regulatory Review (MLR) process and significantly shorten review and approval timelines for modular content, thus driving faster speed to market for essential medicines.
The solution makes the process more efficient. It increases speed by eliminating key manual tasks and automating the remaining tasks and it reduces costs by freeing up high-value people to focus on higher value-adding omnichannel activities, while lowering risk of regulatory fines.
It also makes the MLR process more reliable by leveraging AI and machine learning to improve compliance by increasing objectivity and consistency of reviews. Finally, it increases the use of intelligence because the AI engine is consistently learning and improving, prioritizing actions and applying the leading practices.
Twelve machine learning modules make up the solution, with new modules being developed and added over time. Currently available in English, EY Smart Reviewer will also be available in French, German, Spanish, Italian, Japanese and Chinese by early 2022.